Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) a global cannabinoid innovator specializing in the development of pharmaceutical and consumer products announces that it is initiated the process of obtaining a secondary listing on the Australian Stock Exchange (ASX) and expects this process to be completed by calendar Q1 2018. The Company has successfully completed the due diligence and corporate review requirements of the exchange and will now move forward in filing for approval.
In correlation with this dual listing, the company announces a strategic investment of $1MM CDN at $.25 with a full 2-year warrant at $.75 with a 30-day acceleration clause if the stock trades above $1.00 for 10 consecutive days. This capital will be used to fund the operational expansion into Australia and certain regions of South East Asia.
Marcos Agramont, CEO of Isodiol International Inc, stated “We are excited to be expanding our footprint into Australia which we see as the gateway into Asia. We have seen incredible traction of our flagship product Isoderm™ in Latin America and we envision similar traction in the Australasia region. Obtaining a public listing on the ASX allows us to solidify our footprint, as well as access to the capital markets that a company would not have being based in Canada. This industry is in its infancy stage in Australia and we believe we can become the leaders in innovation and product development within the region. This listing will complement our current listings on the Canadian Stock Exchange (CSE), the OTC in the US and Germany.”
credit:420intel.com
